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The use of exogenous iron by cyclists is quite widespread despite
controversies and lack of scientiﬁc evidence linking this supplementa-
tion with improved performance [1]. Although iron is essential for cell
proliferation, eritropoese and oxy-reduction reactions, it is easily
accumulated in vital organs. Iron overload is responsible for the
production of reactive oxygen species that can cause organic dysfunc-
tion [2,3]. In the heart, iron overload cardiomyopathy (IOC) is a
secondary variety of cardiomyopathy caused by iron accumulation in
the myocardium resultant from genetic diseases of iron metabolism or
multiple transfusions [4,5]. Based on this knowledge, we tested the
hypotheses that athlete users of iron supplementationwould show iron
accumulation in abdominal organs as well as the heart and would
present cardiac ﬁbrosis. A second aimwas to link ferritin level with iron
dose, organic ironaccumulation, lengthof use anddeliveryconsumption
method, beyond the relationships between length and interruption of
iron use and organic iron accumulation.
Eighteenhealthyelite cyclists (29.6±4.3 years old)users and former
users of parenteral and/or enteral iron supplementation were included
in the study after signing a written informed consent. This study was
approved by the Ethics Committee for Analysis of Research Projects
(# 09/1157) of the Hospital Israelita Albert Einstein.
A 1.5 MRI imaging system (General Electric, Milwaukee, Wisconsin,
USA) was used for T2* imaging and iron quantiﬁcation [6]. T2* values for
abdominal organs were: light (12.5–4.7 ms), moderate (4.6–2.3 ms) and
severe (2.3–1.5 ms). T2*N20 ms was normal for the heart. Hepatic iron
concentration (HIC) was: light (2.2–5.6 mg·g−1), moderate (5.6–
11.2 mg·g−1) and severe (11.2–16.7 mg·g−1) [6,7]. All exams were
performedwith an infusion of intravenous contrast (gadolinium). Serum
ferritin levels (normal values between 22 and 322 ng·ml−1) and HFE
gene mutations (H63D, C282Y and S65C) were evaluated.
The magnitude and direction of the correlations between the
variables were veriﬁed by Pearson product–moment correlation
coefﬁcient. Ferritin partitions were considered to calculate the mean
organ iron accumulation. Data were expressed as mean and standard
deviation. P≤0.05 was considered statistically signiﬁcant.
The lengthof parenteral andenteral useof ironwas4.8±3.4 years and
4.3±3.6 years, respectively. The iron total dose (parenteral plus enteral)
usedwas46.0±48.9 gand11cyclists had stopped theuseof iron for 1.8±
2.0 years at the moment of the evaluations. Hepatic (67%) and splenic
(50%) iron accumulations were detected in the athletes. Pancreatic and
cardiac iron accumulations were not observed. Ferritin levels were
elevated in 83% of the athletes. No athlete had C282Yand S65Cmutations,
but 4 athletes had H63D mutation (all heterozygotes). Pearson's
correlation demonstrated a positive relationship between ferritin and
dose of parenteral iron (r=0.51, P=0.03). High levels of ferritin were
Table 2
Electrical characteristics of pacing leads.
Sensing (mV) Impedance (Ω) Pulse threshold
A V A V A V
Predischarge
(n=250)
3.1±1.7 10.6±5.3 563±160 721±218 0.9±0.6 0.8±0.7
6 months
(n=224)
2.9±1.7 10.4±5.1 527±110 563±103 0.6±0.3 0.7±0.3
12 months
(n=160)
2.8±1.7 9.4±4.5 505±103 562±107 0.6±0.2 0.8±0.4
24 months
(n=113)
2.6±1.9 9.5±5.5 545±123 505±133 0.6±0.2 0.8±0.7
Values are mean±SD. Pacing thresholds were determined in volts at a pulse width of
0.5 ms.
A = atrial lead; N = number in parentheses indicates the number of patients tested at
each time point; V = ventricular lead.
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related to smaller values of hepatic (r=−0.83, P=0.00002), splenic
(r=−0.76, P=0.0003) and pancreatic T2* (r=−0.55, P=0.02).
Positive correlation between ferritin and HIC was observed (r=0.89,
P=0.000001). However, there was no relationship between the levels of
ferritin and iron cardiac accumulation (r=−0.37, P=0.13) (Fig. 1). The
mean values of iron accumulation according to ferritin partitions are
presented inTable 1a. Amore precise cutoff value of ferritinwas proposed
to indicate the beginningof hepatic iron accumulation (Table 1b). Hepatic
and splenic T2* were correlated with the length of parenteral use of iron
(r=−0.61, P=0.01 and r=−0.60, P=0.01, respectively) but did not
correlate with the length of parenteral iron interruption.
The present study conﬁrmed that iron supplementation taken by
cyclists leads to hepatic and splenic iron accumulation related to the
parenteral delivery consumption method, but not veriﬁed pancreatic or
cardiac iron accumulation or cardiac ﬁbrosis. Accordingly, exogenous use
of iron can mimic genetic diseases of iron metabolism such as beta
thalassemia. In these patients liver is a target organ to be affected by iron
overload when ferritin levels exceed 1000 ng·ml−1 [3,8]. On the other
hand, the high doses of iron supplementationwere not sufﬁcient to cause
cardiac accumulation or damage. Two hypotheses could be raised to
account for this result: 1) low levels of serum ferritin, which were
insufﬁcient for cardiac accumulation. In fact, our athletes had lower levels
of serum ferritin compared with patients with hematological disease.
Jensen et al. [9] observed the heart's iron accumulation in patients with
transfusional iron overload when ferritin levels are greater than
1800 ng·ml−1; and 2) different mechanisms of cardiac iron accumula-
tion between hematological disease and exogenous use of iron.
The prevalence of HFE gene mutations was low in the cyclists
(22%). Although ferritin levels were high in 50% of the athletes with
H63D mutation, no correlation was observed between these two
variables.
Fig. 1. Pearson's correlations between ferritin levels and organic iron accumulation in cyclists.
Table 1
Hepatic and splenic iron accumulations according to ferritin partitions in all cyclists
(N=18).
Ferritin (ng·ml−1) Hepatic T2* (ms) HIC (mg·g−1) Splenic T2* (ms)
a
Up to 300 29.7±4.1 1.1±0.2 45.0±11.0
301–1000 11.4±4.9 2.9±1.4 17.4±9.1
1001–2300 2.9±1.5 10.8±4.5 7.3±4.2
b
Up to 600 21.3±8.4 1.5±0.5
601–1000 6.5±1.6 4.2±0.9
1001–1500 3.6±1.5 8.4±3.9
1500–2300 1.8±0.3 14.7±2.1
HIC — hepatic iron concentration. Data are mean±SD.
2342 Letters to the Editor
Although a great part of our athletes was of former users of iron we
donot believe that this fact could inﬂuence theﬁnding of no cardiac iron
accumulation since hepatic and splenic iron accumulations were
independent of the length of iron suspension and considering that
there is no passive excretion of iron accumulation by the organs.
Considering the level of hepatic and splenic iron accumulation
according to the ferritin levels we could suggest that athletes with
ferritin levels above 1000 ng·ml−1 and a long history of exogenous
parenteral use of iron could be more bound to moderate and severe
hepatic iron accumulation and should receive more aggressive treat-
ment and orientation about the consequences of the use of iron.
This research highlights the importance of questioning the athletes
about their iron use, mainly cyclists, and serum ferritin levels are
suggested to be considered in the evaluation of these athletes. The
negative ﬁndings of the heart do not allow the discontinuation of
follow-up of these athletes.
This study was supported by Fundação de Amparo à Pesquisa do
Estado de São Paulo [FAPESP#2009/08008-5]. We thank the Pharma-
ceutical Valeria Armentanodos Santos for converting the doses of iron in
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Questioning the validity of a recent randomized trial on paricalcitol in patients with
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We readwith interest the randomized clinical trial by Thadhani et al.
appraising the impact of an active vitamin D compound (paricalcitol) in
patients with echocardiographic evidence of cardiac hypertrophy [1], as
well as the accompanying editorial by Anker and von Haehling [2].
However, the study and editorial conclusions that paracalcitol did not
signiﬁcantly impact on left ventricularmass indexor severalmeasuresof
diastolic dysfunction cannot be considered reliable given the several
major shortcomings of the study.
First, the main selection criterion for study enrolment was transthor-
acic echocardiographic evidence of mild to moderate left ventricular
hypertrophy(septalwall thicknessof 1.1–1.7 cm inwomenand1.2–1.8 cm
in men) without asymmetric septal hypertrophy or valvular disease.
However, magnetic resonance imaging (MRI), also performed at baseline,
showed thatmost patients hadno signiﬁcant left ventricular hypertrophy.
Indeed, we found major differences between echocardiographic and
MRI values for left ventricular mass index (LVMI, e.g., 53.5 g/m2 versus
23.7 g/m2). Given thatMRI should be considered the gold standard test to
deﬁne cardiac hypertrophy, it appears clear that included patients had
very mild hypertrophy at best [3]. Thus, we cannot extrapolate from the
study results what would have been the impact of paracalcitol in patients
withMRI evidence of moderate or severe hypertrophy. Second, the above
ﬁndings are conﬁrmed by the fact that most patients (96%) had
hypertension, but already well controlled (78% in the paracalcitol group
used rennin–angiotensin–aldosterone system inhibitors and 39% used
diuretics). Such satisfactory blood pressure control may have attenuated
an otherwise clinically relevant underlying treatment effect.
Third, there are signiﬁcant discrepancies in MRI-based LVMI in a
prior work published in the American Journal of Nephrology in 2011 [4],
and the present work [1]. Such discrepancies may suggest selective
analysis and reporting of the data, which could explain the apparently
non-signiﬁcant ﬁndings for the primary end-point.
Fourth, the low power of the trial to recognize the effect of this
active vitamin D compound can be inferred by the relatively limited
follow-up duration (48 weeks), as amuch longer timemay be required to
reduce left ventricular hypertrophy [3]. Indeed, the fact that paracalcitol
was already exerting a beneﬁcial effect on hypertrophy is shown by the
signiﬁcant improvement in left atrial indexes, including left atrial volume
index (p=0.001). It is well established that left atrial changes predate
those in the left ventricle in patients with cardiac hypertrophy, and
accordingly it is highly plausible that such beneﬁcial effects of paracalcitol
on left atrial anatomic and functional parameters would have been
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